Are you ready to amplify your academic presence and connect with a global network of researchers? Join the Scholar Indexing Society and elevate your research to new heights!
This editorial discusses the efficacy and safety of automated insulin delivery (AID) systems for type 2 diabetes, based on a clinical trial by Kudva et al. involving 319 insulin treated patients. The AID group using the t:slim X2 pump with Control IQ technology saw a significant reduction in glycated hemoglobin levels (from 8.2% to 7.3%) and increased time in the target glucose range (70–180 mg/dL). Despite a slight weight gain (2.4 kg) and one severe hypoglycemia event unrelated to the device, the system demonstrated promise. Challenges include cost, training demands, and healthcare system barriers to widespread adoption.